A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer's Disease.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Oct 2018
At a glance
- Drugs Pimavanserin (Primary)
- Indications Aggression; Agitation
- Focus Adverse reactions
- Sponsors Acadia Pharmaceuticals
- 28 Feb 2018 Planned number of patients changed from 432 to 111.
- 28 Feb 2018 Planned End Date changed from 1 Jun 2020 to 1 Aug 2019.
- 28 Feb 2018 Planned primary completion date changed from 1 May 2020 to 1 Jul 2019.